Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma?

European Journal of Nuclear Medicine

Volumn 29, Issue 9, 2002, Pages 1248-1256

  Behr, Thomas M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD37 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOPHOSPHAMIDE; EPRATUZUMAB; ETOPOSIDE; HLA DR ANTIGEN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HEART FAILURE; HUMAN; ISOTOPE LABELING; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; RADIATION DOSE; RADIATION PNEUMONIA; RADIOIMMUNOTHERAPY; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE;

EID: 0036373378     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0928-9     Document Type: Review

References (38)

1. 1. DM Goldenberg 2001 Radioimmunotherapy LM Freeman Nuclear medicine annual 2001 Lippincott Williams and Wilkins Philadelphia 167 206 Goldenberg DM. Radioimmunotherapy. In: Freeman LM, ed. Nuclear medicine annual 2001. Philadelphia: Lippincott Williams and Wilkins; 2001:167–206.
2. 2. DM Goldenberg 2002 Targeted therapy of cancer with radiolabeled antibodies J Nucl Med 43 693 713 1:CAS:528:DC%2BD38XktlOlur0%3D 11994535 Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43:693–713.
3. 3. EJ Postema OC Boerman WJ Oyen JM Raemaekers FH Corstens 2001 Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma Eur J Nucl Med 28 1725 1735 1:CAS:528:DC%2BD3MXnvFGhtrk%3D 11702116 10.1007/s002590100570 Postema EJ, Boerman OC, Oyen WJ, Raemaekers JM, Corstens FH. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma. Eur J Nucl Med 2001; 28:1725–1735.
4. 4. TM Behr B Wörmann M Gramatzki J Riggert S Gratz M Béhé F Griesinger RM Sharkey HJ Kolb W Hiddemann DM Goldenberg W Becker 1999 Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies Clin Cancer Res 5 3304 3314 Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W. Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999; 5:3304–3314.
5. 5. SJ DeNardo LA Kroger MR MacKenzie GR Mirick S Shen GL DeNardo 1998 Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody Cancer Biother Radiopharm 13 1 12 1:CAS:528:DyaK1cXitFemu7k%3D 10850337 10.1089/cbr.1998.13.1 DeNardo SJ, Kroger LA, MacKenzie MR, Mirick GR, Shen S, DeNardo GL. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. Cancer Biother Radiopharm 1998; 13:1–12.
6. 6. TM Behr RM Sharkey ME Juweid RM Dunn Z Ying CH Zhang JA Siegel DM Goldenberg 1997 Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies J Nucl Med 38 409 418 1:CAS:528:DyaK2sXitleit78%3D 9074529 Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med 1997; 38:409–418.
7. 7. OW Press JF Eary FR Appelbaum 1993 Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support N Engl J Med 329 1219 1224 1:STN:280:DyaK2c%2FhvFGgtw%3D%3D 7692295 10.1056/NEJM199310213291702 Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219–1224.
8. 8. NA Marshall VT DeVita Jr 1999 Hodgkin’s disease and transplantation: a room with a (nontransplanter’s) view Semin Oncol 26 67 73 1:STN:280:DyaK1M7ntFGksw%3D%3D 10073563 Marshall NA, DeVita VT Jr. Hodgkin’s disease and transplantation: a room with a (nontransplanter’s) view. Semin Oncol 1999; 26:67–73.
9. 9. F Montemurro NT Ueno G Rondon M Aglietta RE Champlin 2000 High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends Clin Breast Cancer 1 197 209 1:STN:280:DC%2BD387mvValsQ%3D%3D 11899644 10.3816/CBC.2000.n.016 Montemurro F, Ueno NT, Rondon G, Aglietta M, Champlin RE. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer 2000; 1:197–209.
10. 10. RM Sharkey TM Behr MJ Mattes R Stein GL Griffiths LB Shih HJ Hansen RD Blumenthal RM Dunn ME Juweid DM Goldenberg 1997 Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 Cancer Immunol Immunother 44 179 188 1:CAS:528:DyaK2sXktl2iurY%3D 9191878 10.1007/s002620050371 Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997; 44:179–188.
11. 11. M Juweid RM Sharkey A Markowitz 1995 Treatment of non-Hodgkin’s lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody Cancer Res 55 5899 5907 Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin’s lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995; 55:5899–5907.
12. 12. DE Tsai SJ Schuster A Matthies HC Moore A Alavi ME Juweid DM Goldenberg EA Stadtmauer 2000 Progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy Clin Lymphoma 1 62 66 1:STN:280:DC%2BD3MnlsVGjsA%3D%3D 11707815 10.3816/CLM.2000.n.006 Tsai DE, Schuster SJ, Matthies A, Moore HC, Alavi A, Juweid ME, Goldenberg DM, Stadtmauer EA. Progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. Clin Lymphoma 2000; 1:62–66.
13. 13. LM Rose CT Deng SL Scott CY Xiong KR Lamborn PH Gumerlock GL DeNardo CF Meares 1999 Critical Lym-1 binding residues on polymorphic HLA-DR molecules Mol Immunol 36 789 797 1:CAS:528:DyaK1MXntlOhs70%3D 10593517 10.1016/S0161-5890(99)00083-8 Rose LM, Deng CT, Scott SL, Xiong CY, Lamborn KR, Gumerlock PH, DeNardo GL, Meares CF. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999; 36:789–797.
14. 14. GL DeNardo SJ DeNardo RT O’Donnell LA Kroger DL Kukis CF Meares DS Goldstein S Shen 2000 Are radiometallabeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma Clin Lymphoma 1 118 126 1:STN:280:DC%2BD3MnlsVCrug%3D%3D 11707820 10.3816/CLM.2000.n.010 DeNardo GL, DeNardo SJ, O’Donnell RT, Kroger LA, Kukis DL, Meares CF, Goldstein DS, Shen S. Are radiometallabeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma. Clin Lymphoma 2000; 1:118–126.
15. 15. GA Wiseman CA White M Stabin WL Dunn W Erwin M Dahlbom A Raubitschek K Karvelis T Schultheiss TE Witzig R Belanger S Spies DHS Silverman JR Berlfein E Ding AJ Grillo-López 2000 Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma Eur J Nucl Med 27 766 777 1:CAS:528:DC%2BD3cXktVOjsL8%3D 10952488 10.1007/s002590000276 Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DHS, Berlfein JR, Ding E, Grillo-López AJ. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000; 27:766–777.
16. 16. GA Wiseman LI Gordon PS Multani TE Witzig S Spies NL Bartlett RJ Schilder JL Murray M Saleh RS Allen AJ Grillo-Lopez CA White 2002 Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial Blood 99 4336 4342 1:CAS:528:DC%2BD38XksFGlu7s%3D 12036859 10.1182/blood.V99.12.4336 Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336–4342.
17. 17. TE Witzig LI Gordon F Cabanillas MS Czuczman C Emmanouilides R Joyce BL Pohlman NL Bartlett GA Wiseman N Padre AJ Grillo-Lopez P Multani CA White 2002 Randomized controlled trial of yttrium-90-labeled Ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin’s lymphoma J Clin Oncol 20 2453 2463 1:CAS:528:DC%2BD38XksFakur0%3D 12011122 10.1200/JCO.2002.11.076 Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled Ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:2453–2463.
18. 18. TE Witzig CA White IW Flinn 2000 Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma (NHL) Blood 96 507 Witzig TE, White CA, Flinn IW, et al. Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma (NHL). Blood 2000; 96:507a (abstract 2183).
19. 19. TE Witzig LI Gordon GA Wiseman 2000 Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin’s lymphoma (NHL) Blood 731 96 Witzig TE, Gordon LI, Wiseman GA, et al. Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin’s lymphoma (NHL). Blood 2000; 96: 731a (abstract 3160).
20. 20. MS Kaminski J Estes KR Zasadny IR Francis CW Ross M Tuck D Regan S Fisher J Gutierrez S Kroll R Stagg G Tidmarsh RL Wahl 2000 Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood 96 1259 1266 1:CAS:528:DC%2BD3cXlvF2it7k%3D 10942366 Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259–1266.
21. 21. MS Kaminski KR Zasadny IR Francis 1993 Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody N Engl J Med 329 459 465 1:STN:280:DyaK3szitl2htQ%3D%3D 7687326 10.1056/NEJM199308123290703 Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329:459–465.
22. 22. M Kaminski AD Zelenetz OW Press 1998 Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma Blood 1296 92 Kaminski M, Zelenetz AD, Press OW, et al. Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma. Blood 1998; 92:1296a (abstract).
23. 23. RL Wahl KR Zasadny J Estes 2000 Single center experience with iodine I-131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL) J Nucl Med 41 79 Wahl RL, Zasadny KR, Estes J, et al. Single center experience with iodine I-131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL). J Nucl Med 2000; 41: 79 (abstract 309).
24. 24. JP Leonard M Coleman L Kostakoglu 1999 Fludarabine monophosphate followed by I-131 tositumomab for untreated low-grade and follicular non-Hodgkin’s lymphoma (NHL) Blood 94 1 90 Leonard JP, Coleman M, Kostakoglu L, et al. Fludarabine monophosphate followed by I-131 tositumomab for untreated low-grade and follicular non-Hodgkin’s lymphoma (NHL). Blood 1999; 94 [Suppl 1]: 90a (abstract 393).
25. 25. OW Press JF Eary FR Appelbaum 1995 Phase II trial of 131IB1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet 346 336 340 1:STN:280:DyaK2MzkvFahuw%3D%3D 7623531 10.1016/S0140-6736(95)92225-3 Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131IB1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336–340.
26. 26. SY Liu JF Eary SH Petersdorf PJ Martin DG Maloney FR Appelbaum DC Matthews SA Bush LD Durack DR Fisher TA Gooley ID Bernstein OW Press 1998 Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue J Clin Oncol 16 3270 3278 1:CAS:528:DyaK1cXmvFGrtLk%3D 9779701 Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16:3270–3278.
27. 27. TA Johnson OW Press 2000 Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience Ann Hematol 79 175 182 1:CAS:528:DC%2BD3cXitlelsrw%3D 10834504 10.1007/s002770050576 Johnson TA, Press OW. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 2000; 79:175–182.
28. 28. OW Press JF Eary T Gooley AK Gopal S Liu JG Rajendran DG Maloney S Petersdorf SA Bush LD Durack PJ Martin DR Fisher B Wood JW Borrow B Porter JP Smith DC Matthews FR Appelbaum ID Bernstein 2000 A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 96 2934 2942 1:CAS:528:DC%2BD3cXnslGnsb8%3D 11049969 Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934–2942.
29. 29. Behr TM, Kaufmann CC, Wörmann B, Riggert J, Gratz S, Béhé M, Griesinger F, Brittinger G, Becker W. High-dose, myeloablative radioimmunotherapy of non-Hodgkin’s lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support.
30. 30. I Barista JE Romaguera F Cabanillas 2001 Mantle-cell lymphoma Lancet Oncol 2 141 148 1:STN:280:DC%2BD387ntFelsA%3D%3D 11902564 10.1016/S1470-2045(00)00255-2 Barista I, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. Lancet Oncol 2001; 2:141–148.
31. 31. TE Witzig CA White GA Wiseman LI Gordon C Emmanouilides A Raubitschek N Janakiraman J Gutheil RJ Schilder S Spies DH Silverman E Parker AJ Grillo-Lopez 1999 Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma J Clin Oncol 17 3793 3803 1:CAS:528:DC%2BD3cXhsVCiug%3D%3D 10577851 Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17:3793–3803.
32. 32. TM Behr F Griesinger J Riggert S Gratz M Béhé CC Kaufmann B Wörmann G Brittinger W Becker 2002 Highdose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study Cancer 94 1363 1372 1:CAS:528:DC%2BD38XitVKhsrk%3D 11877767 10.1002/cncr.10307 Behr TM, Griesinger F, Riggert J, Gratz S, Béhé M, Kaufmann CC, Wörmann B, Brittinger G, Becker W. Highdose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study. Cancer 2002; 94:1363–1372.
33. 33. AK Gopal JG Rajendran SH Petersdorf DG Maloney JF Eary BL Wood TA Gooley SA Bush LD Durack PJ Martin DC Matthews FR Appelbaum ID Bernstein OW Press 2002 High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma Blood 99 3158 3162 1:CAS:528:DC%2BD38XjtlGqsro%3D 11964278 10.1182/blood.V99.9.3158 Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158–3162.
34. 34. DM Goldenberg 1995 Cancer therapy with radiolabeled antibodies CRC Press Boca Raton, Fl. Goldenberg DM, ed. Cancer therapy with radiolabeled antibodies. Boca Raton, Fl.: CRC Press, 1995.
35. 35. TM Illidge S Brock 2000 Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy Curr Pharm Des 6 1399 1418 1:CAS:528:DC%2BD3cXmtFChsbo%3D 10903400 10.2174/1381612003399257 Illidge TM, Brock S. Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr Pharm Des 2000; 6:1399–1418.
36. 36. SJ DeNardo LA Kroger GL DeNardo 1999 A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 11 563 569 1:CAS:528:DyaK1MXmslahsb4%3D 10508716 10.1016/S0952-7915(99)00017-5 DeNardo SJ, Kroger LA, DeNardo GL. A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 1999; 11:563–569.
37. 37. OW Press 1999 Radiolabeled antibody therapy of B-cell lymphomas Semin Oncol 26 58 65 1:CAS:528:DyaK1MXnslGjt78%3D 10561019 Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999; 26:58–65.
38. 38. JM Vose 1999 Antibody-targeted therapy for low-grade lymphoma Semin Hematol 36 15 20 1:CAS:528:DyaK1MXntFSmtrc%3D 10530712 Vose JM. Antibody-targeted therapy for low-grade lymphoma. Semin Hematol 1999; 36:15–20.